undamentalytics Newsletter
Sign in

Profound Medical Corp. (PROF) stock

Add to watchlist

Add holding +

NASDAQ: PROF Nasdaq Health Care Equipment Next results ~November 5, 2026

Profound Medical Corp. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$2.0

Forward price-to-sales vs peers

Base case. Range ~$2.0–$7.6. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Profound Medical Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds18 adding, 22 cuttingOf 5 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Profound Medical Corp.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 68% and a beta of 1.4 against the S&P 500.

Latest results

Earnings per share
-$0.26 against an average estimate of -$0.24: missed by 7.2%
Share reaction
+13.7% in the first session after the results on October 7, 2026, against -0.7% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.20

Profound Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.4%
  • 1 week+21.3%
  • 1 month+15.2%
  • This year-14.5%
  • 1 year+10.9%
  • 5 years-49.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
October 7, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results
  5. Announcement
  6. Leadership
  7. Announcement
  8. Leadership
  9. Announcement
  10. Results
  11. Announcement
  12. Announcement
  13. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Profound Medical Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Profound Medical Corp. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.93 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: no revenue, margin or share count to start from
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.0 ~$2.2–$7.6 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.0 ~$2.0–$7.6 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Profound Medical Corp. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $14m and EPS of −$0.20 (range −$0.22 to −$0.16) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.84 +41% $37m +69%
Next −$0.59 +30% $60m +61%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −0.8% on 90 days ago. In the last 30 days, 2 analysts raised Profound Medical Corp.'s forecast and 0 cut it.

Consensus EPS forecast Profound Medical Corp., last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.84 Current fiscal year, 60 days ago: −$0.87 Current fiscal year, 30 days ago: −$0.86 Current fiscal year, 7 days ago: −$0.86 Current fiscal year, Now: −$0.84 −$0.84 Next fiscal year, 90 days ago: −$0.75 Next fiscal year, 60 days ago: −$0.59 Next fiscal year, 30 days ago: −$0.59 Next fiscal year, 7 days ago: −$0.59 Next fiscal year, Now: −$0.59 −$0.59

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.84−$0.75
60 days ago −$0.87−$0.59
30 days ago −$0.86−$0.59
7 days ago −$0.86−$0.59
Now −$0.84−$0.59

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.24 −$0.26 −7.2%
Mar 2026 −$0.25 −$0.19 +25.2%
Dec 2025 −$0.27 −$0.27 +1.2%
Sept 2025 −$0.38 −$0.26 +30.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202655
  3. Aug 202655

Counts of recommendations published by analysts covering Profound Medical Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.8%
of tradable shares
Days to cover
5.16
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
45%
of shares
Held by insiders
4.1%
of shares
Employees
162
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PROF−45%−3%−22%−12%+5%−15%
Industry peers (median)−7%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PROF25%50%58%42%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PROF−63%−72%−47%−38%−51%−42%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2019: 89% from February 5, 2021 to October 26, 2022. Getting back needed a 783% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.06 – $8.65
From 52-week high
−22.2%
vs 50-day average
+8.1%
vs 200-day average
+1.0%
Volatility (1 year)
68%
Beta vs S&P 500
1.44

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 7 down
typical move ±11.8%
After a week
2 up, 7 down
typical move ±9.1%
After a month
2 up, 6 down
typical move ±17.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 7, 2026 +13.7% −0.7% +8.9% —
August 6, 2026 −7.3% +0.5% −16.5% −13.8%
May 7, 2026 −5.1% +0.5% −0.3% −9.0%
March 5, 2026 −29.0% −1.9% −25.8% −12.3%
October 7, 2025 +16.6% +0.2% +0.9% +1.4%
August 14, 2025 −22.0% −0.2% −15.6% −25.0%
May 8, 2025 −3.7% +0.6% −5.8% +19.5%
March 7, 2025 −7.5% −2.1% −4.7% −35.7%
January 8, 2025 −1.2% −1.4% −3.0% −23.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Recurring Non Capital $9.7M 60.4% ▲ 18.1%
Capital Equipment $6.4M 39.6% ▲ 161.0%
Geography
Region Revenue Share YoY
United States $12.2M 76.1% ▲ 66.6%
Canada $3.1M 19.1% ▲ 26.3%
Germany $773,000 4.8% ▼ 13.2%

From Profound Medical Corp.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$109M
Institutions reporting
56
Shares held vs prior quarter
▲ 1.0%
Positions opened / closed
5 / 5

Top buyers and sellers, Q2 2026: 18 institutions bought and 22 sold ; the biggest buyer was First Eagle Investment Management, LLC (+558K shares) and the biggest seller Velan Capital Investment Management LP (−115K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Fil Ltd $15.8M 2.4M 14.5% ▲ 1.3%
Gagnon Securities LLC $13M 2.0M 12.0% ▲ 0.8%
Royce & Associates LP $8M 1.2M 7.3% ▲ 7.5%
Timelo Investment Management Inc. $7.4M 1.1M 6.8% 0.0%
Gagnon Advisors, LLC $6.4M 962K 5.9% 0.0%
First Eagle Investment Management, LLC $5.9M 880K 5.4% ▲ 172.8%
Rosalind Advisors, Inc. $5.5M 828K 5.1% 0.0%
Z3 Capital Partners, LLC $5.5M 821K 5.0% ▲ 0.4%
Letko, Brosseau & Associates Inc $5.4M 936K 5.0% ▼ 1.8%
Mmcap International Inc. Spc $4.5M 671K 4.1% ▼ 9.9%
Ardsley Advisory Partners LP $3.8M 575K 3.5% 0.0%
Ring Mountain Capital, LLC $3.4M 512K 3.1% ▲ 0.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Profound Medical Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 4 trades and filings

No trades in Profound Medical Corp. disclosed in the last 12 months; 4 earlier trades on record.

  • Tom Malinowski(D-NJ 7):Purchase, $1,001 - $15,000, traded July 21, 2020, filed March 5, 2021
  • Tom Malinowski(D-NJ 7):Purchase, $1,001 - $15,000, traded January 27, 2020, filed August 26, 2021
  • Tom Malinowski(D-NJ 7):Purchase, $1,001 - $15,000, traded January 14, 2020, filed August 26, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

  • October 7, 2026
  • August 6, 2026
  • May 7, 2026
  • March 5, 2026
  • October 7, 2025
  • August 14, 2025

Recent SEC filings

Data status

When each part of this page on Profound Medical Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Profound Medical Corp. in brief

What does Profound Medical Corp. do?
Profound Medical Corp. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Profound Medical Corp.'s stock ticker?
Profound Medical Corp. trades under the ticker PROF on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Profound Medical Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Fil Ltd, Gagnon Securities LLC and Royce & Associates LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
When is Profound Medical Corp.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Profound Medical Corp. announces its own schedule.